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Background – Long-term remission between flares of canine atopic dermatitis (CAD) can be difficult to achieve.
Therefore, additional strategic forms of treatment are needed in order to target flare prevention. The concept of
proactive therapy is recommended in the European guidelines for the treatment of human atopic eczema.
Objectives – To evaluate the efficacy of a proactive treatment regimen with a 0.0584% hydrocortisone ace-
ponate (HCA) spray for CAD.
Animals – Client-owned dogs with spontaneous atopic dermatitis (AD) (n = 41).
Methods – This pilot study was conducted as a randomised, placebo-controlled, double-blinded clinical trial with
an end-point of treatment failure. Dogs were treated once daily to remission, then randomly assigned to receive
either the HCA spray (n = 21) or a placebo (n = 20) spray on two consecutive days each week. All dogs were on
appropriate flea control. No topical or systemic anti-inflammatory or antimicrobial agents were permitted. Inten-
tion-to-treat analysis was used.
Results – At Day 0, all the dogs were in remission or had mild AD based on their Canine Atopic Dermatitis Extent
and Severity Index, version 3 (CADESI-03) scores. The time to relapse was significantly higher in the HCA group
(median 115 d; range 31–260 d) compared to the placebo group (median 33 d; range 15–61 d) (P < 0.0001). No
adverse events were attributable to the HCA spray. Four dogs were lost to follow-up and four were withdrawn
after receiving prohibited medication.
Conclusions and clinical importance – These results indicate that proactive long-term therapy of CAD with an
HCA spray administered on two consecutive days each week is effective and well-tolerated.
Introduction
Canine atopic dermatitis (CAD) is a common, highly pru-
ritic disease characterized by a waxing and waning course
with frequent flares of inflammation. Treatment of severe
and chronic cases can be challenging, and CAD is often
associated with diminished quality of life in dogs and an
economic burden for their owners.1,2
There are several treatment options for acute flares
and chronic disease, which are well described in the liter-
ature and have been summarized in guidelines from the
then International Task Force on Canine Atopic Dermatitis
[now the International Committee for Allergic Diseases in
Animals (ICADA)].3,4 Nevertheless, long-term remission
between flares can be difficult to achieve. Therefore,
additional strategic forms of treatment are needed in
order to target flare prevention.
In humans, there is evidence that clinically normal, non-
lesional atopic skin is, in fact, not ‘normal’. Based on find-
ings that the skin of patients with atopic dermatitis (AD)
has impaired barrier function and subclinical inflamma-
tion, the traditional reactive approach to therapy has been
challenged in recent years by the proactive therapy con-
cept. The latter is defined as a combination of pre-deter-
mined, long-term, low-dose, anti-inflammatory treatment
applied to previously affected areas of skin.5–8 The first
trial with intermittent topical steroid use was published as
early as 1999.9 Today the concept of proactive therapy is
recommended in the European guidelines for treatment
of human atopic eczema.6,10 Similarly, apparently nonle-
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sional skin of atopic dogs exhibits barrier defects and
inflammation.11–13
Hydrocortisone aceponate is a potent steroid with a
low rate of percutaneous absorption and consequently a
low potential for systemic toxicity.14 A 0.0584% hydro-
cortisone aceponate (HCA) spray (Cortavance, Virbac
Animal Health; Carros, France) has been shown to be
highly effective and well tolerated in CAD for up to
84 days,3,15 and it is recommended for the management
of acute flares and chronic AD.4 However, these studies
did not evaluate the long-term efficacy of HCA in prevent-
ing exacerbations of AD once in remission.
The goal of our study was to perform a placebo-con-
trolled, double-blinded pilot study to evaluate the efficacy
of long-term, proactive, intermittent treatment with HCA
in CAD flare prevention.
Materials and methods
Study design
This was a randomized, double-blinded, placebo (vehicle)-controlled,
parallel-grouped study. The primary objective was to evaluate the
efficacy and safety of an HCA twice weekly maintenance regime in
reducing the risk of relapse in CAD.
Subjects
Client-owned dogs with recurrent perennial AD were eligible for the
study and were recruited during a flare. The clinical diagnosis of AD
was made according to accepted criteria and after ruling out other
causes of pruritus.16 Briefly, there must have been a compatible his-
tory, clinical criteria strongly associated with the disease, exclusion
of other pruritic skin diseases with no response to an 8-week (mini-
mum) elimination diet trial consisting of either home-cooked single
protein or commercial hydrolysed protein diet, an 8-week veterinar-
ian-approved flea control regimen, and exclusion of sarcoptic mange
by trial therapy and/or negative serology. At least one positive reac-
tion to a perennial allergen on intradermal or serological testing was
required for enrolment.
Exclusion criteria included any conditions for which topical corti-
costeroids were contraindicated, other dermatological conditions
that might have prevented accurate assessment of AD and any con-
comitant medications that might have interfered with the study’s
outcome. Participating dogs were required to receive appropriate flea
control throughout the trial. Essential fatty acids, allergen-specific
immunotherapy (ASIT) and emollient shampoos were permitted if
they had been used prior to the trial and the dog had stable disease.
No topical or systemic anti-inflammatory (besides HCA) or antimicro-
bial agents were permitted during the trial.
Owners provided written informed consent for inclusion of their
dogs in the study.
Trial protocol
Phase 1 (stabilization): 0.0584% HCA spray was applied to affected
skin according to the manufacturer’s recommendations (i.e. two
pumps at 10 cm distance from the skin, per 100 cm2 surface area)
until remission. Remission was defined as a Canine Atopic Dermatitis
Extent and Severity Index, version 3 (CADESI-03) score of 59 or less,
corresponding to remission or mild CAD.17 Full clinical assessments,
including the CADESI-03 evaluations, were performed every
2 weeks during this stabilization phase.
Phase 2 (evaluation): the duration of clinical remission of AD was
evaluated during use of 0.0584% HCA or a placebo spray, which
were applied on two consecutive days each week (e.g. Saturday and
Sunday) at the previously affected sites.
Experimental design
An unpredictable allocation sequence was generated using four
groups (two placebo and two HCA) to reduce bias among owners
and the investigator. Dogs with AD that fulfilled the admission criteria
and completed Phase 1 were randomly allocated in Phase 2 to
receive either 0.0584% HCA or placebo according to the sequence
established before the trial. Assignment to a group was masked from
the owners and investigator until the trial was completed. The HCA
spray and the placebo were supplied in identical bottles. They were
pre-packaged and labelled A, B, C or D. A single investigator
assessed all of the treatment outcomes and was not involved in
treatment allocation. A student or a nurse dispensed the bottles to
the owners and maintained the corresponding records.
Participants were assessed every 2 weeks for the first 45 days of
the trial, then monthly (or sooner in the case of relapse). The investi-
gator performed a thorough clinical examination at each visit, record-
ing and investigating any adverse events including cutaneous
atrophy. The end-point (failure) was considered to be a CADESI-03
score of 60 or above, and/or otitis, pyoderma or pruritus requiring
treatment with a prohibited medication (i.e. topical or systemic anti-
inflammatory or antimicrobial treatment). Dogs were also withdrawn
for poor compliance and owners were free to withdraw from the trial
at any point. Elapsed time from Day 0 to the end-point was recorded.
Upon failure, dogs were removed from the study and prescribed
appropriate medications. After a pre-defined period of time
(12 months) the study was concluded.
Custom-made journal forms were given to the owners to record
treatment applications, unexpected occurrences or adverse effects.
Regular telephone calls to the owners were made to obtain updates
on the treatment plan and the dog’s condition. At the end of the trial
the owners were asked to return all bottles (empty or not) so that
compliance could be assessed.
Data analysis
The primary end-point was the time to relapse of clinical signs during
the maintenance phase. On-treatment data were used for intention-
to-treat analysis using the last-observation-carried-forward technique
for dogs that were withdrawn for poor compliance, at the owners’
request, or lost to follow-up. The Kaplan–Meier method was used to
estimate the distribution of time to relapse of AD.
Results
From the group initially enrolled (n = 41), four dogs were
lost to follow-up. Three of these were from the HCA
group; one died from an unrelated cause and the other
two were excluded due to lack of compliance. In addition,
one dog from the placebo group was excluded for non-
compliance. Four dogs from the placebo group were pre-
maturely withdrawn from Phase 2 due to administration
of a prohibited medication.
There were no significant differences in clinical or
demographic baseline values between the two groups
(HCA and placebo) at the beginning of treatment. There
were also no significant differences between dogs that
received ASIT and/or emollient shampoos when com-
pared to those that did not.
Kaplan–Meier survival analysis revealed that the med-
ian time to relapse was 115 d in the HCA group (range
31–260 d) and 33 in the placebo group (range 15–61 d;
Figure 1). Medians between treatment groups differed
significantly (two-tailed P < 0.0001). The risk for flare
development under proactive HCA therapy was 3.5-fold
lower than under placebo therapy. Fifty days after the
beginning of Phase 2 more than 85% of the placebo
group had relapsed in comparison to only two of the HCA
group. Relapse rates in the HCA group were 60% at
100 d and 80% at 180 d. No adverse events attributable
to HCA spray were noted.
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Discussion
Long-term therapy of CAD with HCA spray administered
on two consecutive days each week was effective in
reducing the risk of relapse and was well tolerated in this
group of dogs. Our results show that proactive therapy in
CAD can control residual disease with minimal anti-
inflammatory drug use. To the best of the authors’ knowl-
edge, this is the first randomized, controlled clinical trial
to examine longer term management of CAD with a
proactive regimen using a topical glucocorticoid. The
focus of the trial was on maintaining remission rather
than on initial control of the clinical signs, and assessed
the effect of treatment on the time to relapse, an impor-
tant clinical outcome in this chronic, recurrent skin condi-
tion. This outcome may be beneficial in terms of safety,
tolerance, quality of life and costs. Our results are in line
with recent findings in human AD, where the concept of
proactive therapy is recommended for the treatment of
human atopic eczema.6,10,18
Textbooks and position papers on the treatment of
CAD refer to topical glucocorticoid therapy for visible skin
lesions. However, once there are no longer visible skin
lesions, therapy is often tapered and discontinued. This
treatment concept is now referred to in human medicine
as ‘reactive therapy’.5 Although acute treatment flares
can be managed successfully with this strategy, recur-
rence is the rule if no other forms of therapy are provided.
Proactive therapy begins with intensive topical anti-
inflammatory therapy until lesions are in remission. How-
ever, the novel and pertinent aspect of such therapy is
the subsequent long-term, low-dose, intermittent applica-
tion of the anti-inflammatory agent to the previously
affected skin.19 Acceptance of this concept, even in
human medicine, is new: the immunobiological back-
ground explanation was first published in 2009.20 Accord-
ing to these authors the immunodermatological rationale
to this approach is the ongoing epidermal barrier dysfunc-
tion, the residual inflammatory skin infiltrate and the per-
sistent immunological abnormalities which are all present
but clinically invisible.20 Canine AD shares many clinical
and immunological similarities with its human counter-
part, including evidence of skin barrier dysfunction, per-
sistent inflammation and immunological activation even
in skin that macroscopically appears to be unin-
volved.11,13,21–25 Therefore, the underlying logic for the
success and justification of the proactive approach is sim-
ilar in human and canine AD.
As noted in earlier studies, the clinical response to HAC
was quite rapid for the dogs that responded, where clini-
cal remission was achieved within 1 month of initiating
daily treatment.15,26 Intermittent therapy maintained
remission, although the longer term response was vari-
able between dogs. This is similar to results published in
other studies.15,26 Variation in the frequency of long-term
medication needed to maintain remission of AD may be
due to the inherent severity of condition, environment
(e.g. allergen or irritant exposure), and/or genotypic differ-
ences in response to drug therapy or with medication
administration. These results are nevertheless encourag-
ing, as monotherapy for CAD is not normally recom-
mended.4 There was concomitant treatment with ASIT
and/or emollient shampoos in some dogs, but this did not
appear to affect the results. However, it is possible that
additional and better targeted therapies such as skin bar-
rier care, allergen avoidance and ASIT would extend the
duration of remission in more dogs.
The treatment regimens in this study were well toler-
ated. Skin biopsies or adrenocorticotropic hormone
(ACTH)-stimulation tests were not performed, but a previ-
ous study did not find any changes in haematology, bio-
chemistry or ACTH-stimulation tests in dogs treated once
daily, every other day for up to 70 days.27 There was no
clinical evidence of cutaneous atrophy or secondary infec-
tion, as noted in a previous study,26 although cutaneous
atrophy following 14 days of treatment has been
reported.14 Canine AD is usually a lifelong condition and
our study followed dogs for a maximum of 12 months.
Therefore, pharmacovigilance and longer term studies of
safety are warranted.
This study used a validated outcome measure (the
CADESI-03) which has high intra- and interobserver relia-
bility, and provides a relevant and reliable assessment of
clinical severity.17 The lesion scores encompass features
of acute and chronic inflammation, but only provide an
indirect assessment of pruritus through excoriation.
Direct pruritus scores have not been studied or validated
to the same extent, and although a combined Visual Ana-
log Scale (VAS) scale with behavioural descriptors has
been used in other studies with the HCA spray,28 sever-
ity thresholds had not been established at the time
of the study. It was therefore decided to not use speci-
fic pruritus scores as an end-point measure. However,
when pruritus became severe enough to necessitate
pharmacological intervention (in the opinion of either the
owner or investigator), this was used as a study end-
point.
Owner scores for ease of administration, tolerance and
efficacy were not recorded, as the placebo was identical
in form and administration to the active HCA spray and
the end-point was relapse rather than efficacy. Previous
Figure 1. Kaplan–Meier survival analysis for comparing times to
relapse in the therapy of canine atopic dermatitis: ---, placebo group;
—, Cortavance (0.0584% hydrocortisone aceponate spray) group.
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studies reported favourable owner scores for the HCA
spray, albeit with some variation in ease of applica-
tion.15,26 These scores tended to improve with time, pos-
sibly because owners learned to apply the spray more
effectively as they and their dogs adapted to it, and appli-
cation was required less often. It has been difficult to reli-
ably assess quality of life for dogs with AD, but quality of
life questionnaires have been developed and validated
subsequent to the initiation of this study.1,2 Future stud-
ies of therapeutic interventions should evaluate these
alongside other outcomes.
This study was carried out according to Good Clinical
Practice (GCP) standards.29 Rigorous inclusion and exclu-
sion criteria were established before the trial to ensure an
unambiguous diagnosis of AD. Selection bias in breed,
age, sex, weight and clinical severity was not apparent.
Randomised treatment allocation was made according to
a predetermined allocation code. Detection bias by the
investigators was unlikely as they were blinded to treat-
ment allocation, and a dispenser who did not participate
in any outcome assessments performed treatment-
related follow-up. Ideally the bottles would have been
sequentially numbered and each patient assigned their
own number to further minimize any detection bias. How-
ever, the number of dogs, size, range and length of the
study made this impractical. Performance bias was con-
sidered unlikely as concomitant treatments were pre-
defined, stabilized before the trial, maintained during the
trial, and were similar between the placebo and HCA
groups. Attrition bias was potentially present, with eight
dogs withdrawn from the two phases of the study; how-
ever, on-treatment data were available which permitted
ITT analysis that reduces the risk of bias.
In conclusion, this study demonstrated that a 0.0584%
HCA spray was efficacious and well tolerated in the
proactive treatment of CAD. Proactive management to
maintain remission should improve quality of life for dogs
with AD and their owners. Further studies using the HCA
spray and other products are required to determine
whether this approach is as valid in CAD as in human AD.
Acknowledgements
The authors would like to thank FMV-UL Teaching Hospi-
tal staff for their overall involvement in the study and all
participating patient owners.
References
1. Favrot C, Linek M, Mueller R et al. Development of a question-
naire to assess the impact of atopic dermatitis on health-related
quality of life of affected dogs and their owners. Vet Dermatol
2010; 21: 63–69.
2. Linek M, Favrot C. Impact of canine atopic dermatitis on the
health-related quality of life of affected dogs and quality of life of
their owners. Vet Dermatol 2010; 21: 456–462.
3. Schmidt V, McEwan N, Nuttall T. Hydrocortisone aceponate is a
potent and safe glucocorticoid. Vet Dermatol 2009; 20: 199 (Let-
ter).
4. Olivry T, Deboer DJ, Favrot C et al. Treatment of canine atopic
dermatitis: 2010 clinical practice guidelines from the Interna-
tional Task Force on Canine Atopic Dermatitis. Vet Dermatol
2010; 21: 233–248.
5. Wollenberg A, Ehmann LM. Long term treatment concepts and
proactive therapy for atopic eczema. Ann Dermatol 2012; 24:
253–260.
6. Ring J, Alomar A, Bieber T et al. Guidelines for treatment of ato-
pic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Vener-
eol 2012; 26: 1045–1060.
7. Gelmetti C, Wollenberg A. Atopic dermatitis – all you can do
from the outside. Br J Dermatol 2014; 170(Suppl 1): 19–24.
8. Tang TS, Bieber T, Williams HC. Are the concepts of induction of
remission and treatment of subclinical inflammation in atopic
dermatitis clinically useful? J Allergy Clin Immunol 2014; 133:
1615–1625, e1.
9. Van DMJ, Glazenburg EJ, Mulder PG et al. The management of
moderate to severe atopic dermatitis in adults with topical fluti-
casone propionate. The Netherlands Adult Atopic Dermatitis
Study Group. Br J Dermatol 1999; 140: 1114–1121.
10. Ring J, Alomar A, Bieber T et al. Guidelines for treatment of ato-
pic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol
Venereol 2012; 26: 1176–1193.
11. Marsella R, Olivry T, Carlotti DN. Current evidence of skin barrier
dysfunction in human and canine atopic dermatitis. Vet Dermatol
2011; 22: 239–248.
12. Reiter LV, Torres SM, Wertz PW. Characterization and quantifi-
cation of ceramides in the nonlesional skin of canine patients
with atopic dermatitis compared with controls. Vet Dermatol
2009; 20: 260–266.
13. Olivry T. Is the skin barrier abnormal in dogs with atopic dermati-
tis? Vet Immunol Immunopathol 2011; 144: 11–16.
14. Bizikova P, Linder KE, Paps J et al. Effect of a novel topical die-
ster glucocorticoid spray on immediate- and late-phase cuta-
neous allergic reactions in Maltese-beagle atopic dogs: a
placebo-controlled study. Vet Dermatol 2010; 21: 70–79.
15. Nuttall TJ, McEwan NA, Bensignor E et al. Comparable efficacy
of a topical 0.0584% hydrocortisone aceponate spray and oral
ciclosporin in treating canine atopic dermatitis. Vet Dermatol
2012; 23: 4–10, e1–2.
16. Olivry T, for ITFCAD. New diagnostic criteria for canine atopic
dermatitis. Vet Dermatol 2010; 21: 124–127.
17. Olivry T, Mueller R, Nuttall T et al. Determination of CADESI-03
thresholds for increasing severity levels of canine atopic dermati-
tis. Vet Dermatol 2008; 19: 115–119.
18. Darsow U, Wollenberg A, Simon D et al. ETFAD/EADV eczema
task force 2009 position paper on diagnosis and treatment of
atopic dermatitis. J Eur Acad Dermatol Venereol 2010; 24: 317–
328.
19. Wollenberg A, Bieber T. Proactive therapy of atopic dermatitis–
an emerging concept. Allergy 2009; 64: 276–278.
20. Wollenberg A, Frank R, Kroth J et al. Proactive therapy of atopic
eczema – an evidence-based concept with a behavioral back-
ground. J Dtsch Dermatol Ges 2009; 7: 117–121.
21. Wood SH, Clements DN, Ollier WE et al. Gene expression in
canine atopic dermatitis and correlation with clinical severity
scores. J Dermatol Sci 2009; 55: 27–33.
22. Marsella R, Samuelson D, Doerr K. Transmission electron micro-
scopy studies in an experimental model of canine atopic dermati-
tis. Vet Dermatol 2010; 21: 81–88.
23. Popa I, Remoue N, Osta B et al. The lipid alterations in the stra-
tum corneum of dogs with atopic dermatitis are alleviated by
topical application of a sphingolipid-containing emulsion. Clin
Exp Dermatol 2012; 37: 665–671.
24. Popa I, Pin D, Remoue N et al. Analysis of epidermal lipids in
normal and atopic dogs, before and after administration of an
oral omega-6/omega-3 fatty acid feed supplement. A pilot study.
Vet Res Commun 2011; 35: 501–509.
25. Marsella R, Girolomoni G. Canine models of atopic dermatitis: a
useful tool with untapped potential. J Invest Dermatol 2009;
129: 2351–2357.
26. Nuttall T, Mueller R, Bensignor E et al. Efficacy of a 0.0584%
hydrocortisone aceponate spray in the management of canine
atopic dermatitis: a randomised, double blind, placebo-controlled
trial. Vet Dermatol 2009; 20: 191–198.
© 2016 ESVD and ACVD, Veterinary Dermatology, 27, 88–e25. 91
Proactive therapy for canine atopy
27. Schmidt V, McEwan N, Nuttall T. Hydrocortisone aceponate. J
Small Anim Pract 2009; 50: 317 (Letter).
28. Hill PB, Lau P, Rybnicek J. Development of an owner-assessed
scale to measure the severity of pruritus in dogs. Vet Dermatol
2007; 18: 301–308.
29. Olivry T, Foster AP, Mueller RS et al. Interventions for atopic
dermatitis in dogs: a systematic review of randomized controlled
trials. Vet Dermatol 2010; 21: 4–22.
Resume
Contexte – Une remission a long terme entre les crises de dermatite atopique canine (DAC) peut être diffi-
cile a obtenir. Ainsi, de nouvelles strategies therapeutiques sont necessaires afin de cibler et de prevenir
les crises. Le concept de therapie proactive est recommande en Europe pour le traitement de l’eczema ato-
pique de l’homme.
Objectifs – Evaluer l’efficacite d’un traitement proactif pour la DAC avec un spray a 0.0584% d’aceponate
d’hydrocortisone (HCA).
Sujets – Les chiens de proprietaires atteints de dermatite atopique spontanee (AD) (n = 41).
Methodes – Cette etude pilote a ete menee en tant qu’essai clinique en double aveugle, contrôlee contre
placebo et randomisee avec l’echec de traitement en critere d’evaluation. Les chiens ont ete traite une fois
par jour jusqu’a remission puis assignes au hasard pour recevoir soit le spray HCA (n=21) soit le spray pla-
cebo (n=20) deux jours consecutifs chaque semaine. Tous les chiens recevaient un traitement antipuce
correct. Aucun agent antimicrobien ou anti-inflammatoire topique ou systemique n’etait autorise. Une ana-
lyse en ITT a ete utilisee.
Resultats – A jour 0, tous les chiens etaient en remission ou presentait une AD moderee basee sur leurs
scores de CADESI-03 (Canine Atopic Dermatitis Extent and Severity Index, version 3). Le temps de rechute
etait significativement plus eleve dans le groupe HCA (mediane 115 d; ecart 31–260 d) compare au groupe
placebo (mediane 33 d; ecart 15–61 d) (P < 0.0001). Aucun effet secondaire n’etait attribuable au spray
HCA. Quatre chiens ont ete perdus de vue et quatre ont ete retires de l’etude ayant recu un traitement
non-autorise.
Conclusions en importance clinique – Ces resultats indiquent qu’un traitement proactif sur le long terme
de la DAC avec un spray HCA administre deux jours consecutifs chaque semaine est efficace et bien
tolere.
Resumen
Introduccion – la remision a largo plazo entre ataques de dermatitis atopica canina (CAD) puede ser difıcil
de conseguir. Por lo tanto, se necesitan estrategias adicionales de tratamiento para prevenir la aparicion de
esos ataques. El concepto de terapia proactiva esta recomendado en los parametros europeos para el tra-
tamiento del eccema atopico humano.
Objetivos – evaluar la eficacia de un regimen de tratamiento proactivo con un espray de 0,0584% de ace-
ponato de hidrocortisona (HCA) para CAD.
Animales – perros de propietarios privados con dermatitis atopica espontanea (AD) (n = 41).
Metodos – este estudio piloto fue conducido como un estudio clınico al azar, controlado por placebo y
doble ciego con un punto final de fallo del tratamiento. Los perros pueden fueron tratados una vez al dıa
hasta la remision, y despues asignados al azar para recibir bien el espray de HCA (n = 21) o un espray pla-
cebo (n = 20) en dos dıas consecutivos cada semana. Todos los perros estaban con un control apropiado
frente a las pulgas. No se permitieron agentes topicos o sistemicos antiinflamatorios ni antimicrobianos.
Se utilizo un analisis de intencion de tratar.
Resultados – en el dıa cero, todos los perros estaban en remision o tenıan dermatitis atopica leve basado
en su ındice de extension y severidad de dermatitis atopica canina, version tres (CADESI-03). El tiempo
hasta la reaparicion fue significativamente mayor en el grupo tratado con HCA (media 115 dıas; rango 31 a
260 dıas, comparado con el grupo placebo (media 33 dıas, rango de 15-61 dıas) (P <0,0001). No se observa-
ron efectos adversos atribuidos al espray de HCA. Cuatro perros se perdieron al seguimiento y cuatro per-
ros fueron desechados del estudio tras recibir medicacion prohibida.
Conclusion e importancia clınica – estos resultados indican que la terapia proactiva a largo plazo de un
espray de HCA administraba en dos dıas consecutivos cada semana es efectiva y bien tolerada.
Zusammenfassung
Hintergrund – Es kann zwischen den Sch€uben der atopischen Dermatitis des Hundes (CAD)schwierig sein
eine Langzeitremission zu erzielen. Daher sind zus€atzliche Behandlungsstrategien n€otig, um gezielt Sch€ube
zu verhindern. Das Konzept einer proaktiven Therapie wird in den Europ€aischen Richtlinien zur Behandlung
des atopischen Ekzems beim Menschen empfohlen.
Ziele – Eine Evaluierung der Wirksamkeit einer proaktiven Behandlung mit einem 0,05845%igem Hydro-
cortison Aceponate (HCA) Spray bei CAD.
Tiere – Hunde in Privatbesitz mit spontaner atopischer Dermatitis (AD)(n=41).
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Methoden – Diese Pilotstudie wurde als randomisierte, Plazebo-kontrollierte, doppelblinde klinische Stu-
die mit Versagen in der Endpunktstudie durchgef€uhrt. Die Hunde wurden bis zur Remission einmal t€aglich
behandelt, danach wurden sie zuf€allig eingeteilt, um entweder HCA Spray (n=21) oder Plazebo (n=20)
Spray an zwei aufeinanderfolgenden Tagen jeder Woche zu erhalten. Alle Hunde hatten eine geeignete
Flohprophylaxe. Es waren keine topischen oder systemischen Entz€undungshemmer oder Antibiotika
erlaubt. Es wurde die Intention-to-treat Analyse verwendet.
Ergebnisse – Am Tag 0 befanden sich alle Hunde in Remission oder zeigten eine milde AD nach dem
Canine Atopic Dermatitis Extent and Severity Index, Version 3 (CADESI-03). Die Zeit bis zur Wiederkehr
von Symptomen war in der HCA Gruppe signifikant l€anger (Median 115d; Spannweite 31-260d) im Ver-
gleich zur Plazebogruppe (Median 33d; Spannweite 15-61d)(P<0,0001). Bei der Verwendung des HCA
Sprays wurden keine Nebenwirkungen beobachtet. Bei vier Hunden gab es keinen Follow-up und vier wur-
den aus der Studie genommen, nachdem sie eine unerlaubte Medikation bekommen hatten.
Schlussfolgerungen und klinische Bedeutung – Diese Ergebnisse zeigten, dass die proaktive Langzeit-
therapie bei CAD mit HCA Spray – verabreicht an zwei aufeinanderfolgenden Tagen pro Woche effektiv ist
und gut toleriert wird.
要約
背景 – イヌアトピー性皮膚炎(CAD)の炎症の長期的な寛解を得ることは困難となりえる。それゆえに、追加の治療の
戦略的方法が増悪の予防のために必要である。積極的な治療の概念が、ヨーロッパのヒトのアトピー性皮膚炎の治
療のガイドラインでは奨励されている。
目的 – CADのための0.0584%ヒドロコルチゾールアセポネート(HCA)スプレーを用いた、積極的な治療方法の効果を評
価すること。
供与動物 – 自然発症性アトピー性皮膚炎(AD)の飼い犬(n=41)
方法 – この試験的研究は、治療の失敗を終点としたランダム化二重盲検プラセボ比較試験として実施した。イヌを寛
解まで1日1回治療し、その後、無作為に1週間毎に連続した2日、HCAスプレー(n=21)あるいはプラセボ(n=20)スプ
レーの塗布のいずれかに割り当てた。すべてのイヌに適切なノミ予防を行った。外用剤や全身投与の抗炎症剤や抗菌
物質はいずれも禁止された。包括解析を解析に使用した。
結果 – 0日目に、すべてのイヌは寛解状態あるいは、Canine Atopic Dermatitis Extent and Severity
Index、バージョン3(CADESI-03)スコアを基に評価した軽度のADであった。再発までの期間はプラセボ対照群(平
均33日; 範囲15–61日)と比較し、HCA群(平均115日; 範囲31–260日)で有意に長かった(P < 0.0001)。HCAスプレ
ーに起因した有害事象は報告されなかった。4頭が追跡不可能になり、4頭が禁止された薬剤投与後に脱落となっ
た。
結論および臨床的な重要性 – これらの結果は、HCAスプレーを週に連続した2日間塗布する積極的なCADの長期的
治療が、効果的であり、良好な耐容性を示すことを示唆している。
摘要
背景 – 犬异位性皮炎(CAD)很难做到长时间症状缓解。但是为了预防发病,也需要其他治疗形式。欧洲人异
位性湿疹治疗指南提出前瞻性治疗概念。
目的 – 使用0.0584%氢化可的松醋丙酯(HCA)喷雾治疗CAD,评估此前瞻性治疗方法效果。
动物 – 患自发性异位性皮炎(AD) (n = 41)家养犬。
方法 – 初步研究使用随机、安慰剂对照、双盲临床实验,并以治疗失败为终点。犬每日治疗直至缓解期,然
后随机给予HCA喷雾(n = 21)或安慰剂喷雾(n = 20),每周连续两天使用。所有犬均需适当的跳蚤控制。期间
禁用局部或全身性抗炎药或抗菌剂。使用意向处理分析法。
结果 – 第0天,依据犬异位性皮炎程度和严重指数第3版(CADESI-03)评估,所有犬均处于缓解期或轻度AD。
HCA组(中值115 天; 范围 31–260 天)复发时间明显长于安慰剂对照组(中值33 天; 范围15–61 d) (P < 0.0001).
HCA喷雾组无不良反应。4只犬未能跟踪随访,4只犬未遵守禁止使用药物约定。
总结和临床意义 – 结论表明,每周连续2天使用HCA喷雾,长期前瞻性治疗CAD有效且耐受良好。
Proactive therapy for canine atopy
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